Two years after PhII setback, Jounce's lead I/O drug flops again despite biomarker approach

Amber Tong

When Jounce Therapeutics’ lead drug, vopratelimab, failed to clear the hurdle in a Phase II trial for non-small cell lung cancer, execs pinned their hopes …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Two years after PhII setback, Jounce's lead I/O drug flops again despite biomarker approach

Amber Tong

Sign up to read this article for free.

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

GSK makes case for Blenrep's return with new blood cancer survival data

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Two years af­ter PhII set­back, Jounce's lead I/O drug flops again de­spite bio­mark­er ap­proach

Amber Tong

Sign up to read this article for free.

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Two years after PhII setback, Jounce's lead I/O drug flops again despite biomarker approach

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

GSK makes case for Blenrep's return with new blood cancer survival data

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?